Cormorant Asset Management, LP, Director Other at Design Therapeutics, Inc. (DSGN), bought 5,114,844 shares at $20.00 ($15.0M) on 2021-03-30, disclosed to the SEC on 2021-04-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 4,364,844 | $0 | 0.0% |
| 2 | $20.00 | 750,000 | $15.0M | 100.0% |
| Total | $2.93 avg | 5,114,844 | $15.0M | 100% |
| Filing → |
| DRUG | BUY | 2024-11-06 | $8.0M | — | Filing → |
| EYPT | BUY | 2024-05-08 | $20.2M | — | Filing → |
| CRBP | BUY | 2024-02-06 | $14.3M | — | Filing → |